Merck & Co., Inc. (NYSE:MRK) Sees Significant Decrease in Short Interest
Merck & Co., Inc. (NYSE:MRK) was the recipient of a significant decrease in short interest during the month of October. As of October 31st, there was short interest totalling 19,860,000 shares, a decrease of 7.4% from the September 30th total of 21,440,000 shares. Currently, 0.8% of the company’s stock are sold short. Based on an average daily trading volume, of 8,190,000 shares, the days-to-cover ratio is currently 2.4 days.
Shares of NYSE:MRK traded up $0.05 during midday trading on Tuesday, hitting $84.18. The company’s stock had a trading volume of 2,860,728 shares, compared to its average volume of 9,152,435. The stock has a market capitalization of $216.15 billion, a price-to-earnings ratio of 19.40, a PEG ratio of 1.84 and a beta of 0.54. The stock’s 50 day simple moving average is $84.06 and its 200 day simple moving average is $83.17. Merck & Co., Inc. has a fifty-two week low of $70.89 and a fifty-two week high of $87.35. The company has a debt-to-equity ratio of 0.84, a quick ratio of 0.98 and a current ratio of 1.26.
Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $1.51 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.24 by $0.27. The company had revenue of $12.40 billion for the quarter, compared to the consensus estimate of $11.59 billion. Merck & Co., Inc. had a return on equity of 48.16% and a net margin of 20.26%. The firm’s revenue was up 14.9% compared to the same quarter last year. During the same period last year, the business posted $1.19 earnings per share. As a group, analysts anticipate that Merck & Co., Inc. will post 5.16 EPS for the current year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in MRK. Titan Capital Management LLC CA bought a new position in shares of Merck & Co., Inc. during the 2nd quarter worth about $25,000. LFA Lugano Financial Advisors SA boosted its stake in Merck & Co., Inc. by 250.0% in the 2nd quarter. LFA Lugano Financial Advisors SA now owns 315 shares of the company’s stock worth $26,000 after buying an additional 225 shares during the last quarter. JJJ Advisors Inc. acquired a new stake in Merck & Co., Inc. in the 2nd quarter worth about $27,000. Cumberland Partners Ltd acquired a new stake in Merck & Co., Inc. in the 2nd quarter worth about $40,000. Finally, Fusion Family Wealth LLC boosted its stake in Merck & Co., Inc. by 268.2% in the 2nd quarter. Fusion Family Wealth LLC now owns 486 shares of the company’s stock worth $41,000 after buying an additional 354 shares during the last quarter. Institutional investors and hedge funds own 74.84% of the company’s stock.
About Merck & Co., Inc.
Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.
Featured Story: What is the outlook for the FAANG stocks?
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.